

September 30, 2026



Upcoming Conferences and Events in October

CAMBRIDGE, Mass., September 30, 2026 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming October 2026 conferences and events, and will be available for one-on-one meetings.

Details are as follows:

H.C. Wainwright Biotech On Tap 2026

Date: September 30-October 2

Location: Munich, Germany

Participant: Neil Warma, Chief Executive Officer, ProMIS Neurosciences

Lausanne XIII 13th Annual Workshop

Date: October 6-8, 2026

Location: Lausanne, Switzerland

Participant: Neil Warma, Chief Executive Officer, ProMIS Neurosciences

The Lausanne Workshop is an annual global convening dedicated to stopping Alzheimer's disease. Since 2014, it has united leaders from industry, government, academia, and civil society to drive candid, solutions-focused dialogue.

Chardan's 10th Annual Healthcare Conference

Date: Tuesday, October 20, 2 pm. ET

Location: New York, NY

Panel title: Targeting Neurodegenerative & Neuromuscular Disease: ALS, DMD, Alzheimer's & Parkinson's

Participants: Larry Altstiel, Chief Medical Officer, ProMIS Neurosciences; Moderated by Keay Nakae, Director of Research and a Senior Research Analyst at [Chardan Capital Markets](#)

Greater Boston Walk to End Alzheimer's

Date: Sunday, October 25

Location: Cambridge, MA

About ProMIS Neurosciences Inc.

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded

protein diseases. The Company's proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's disease (PD). ProMIS' lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer's disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

Investor Relations Contact:

Carie Pierce, VP, Investor Relations & External Affairs
IR@promisneurosciences.com